Versameb AG, a Swiss-based pre-clinical stage company, announced on Tuesday that it has named Dr Alexandre LeBeaut, MD as the chairman of the board, effective immediately.

Dr LeBeaut has more than two decades of global R&D leadership experiences, successfully providing multiple medicines to market in immunology, oncology, gastroenterology, cardio-metabolic and infectious diseases. He is a seasoned R&D executive with leadership experience at global biopharmaceutical companies including Schering-Plough Research Institute, Novartis Pharmaceuticals, Sanofi, Axcan Pharmaceuticals and Bluebird Bio. He has worked as executive vice-president R&D and chief scientific officer at Ipsen in the US, CEO of the Institute for Advanced Clinical Trials for Children and served as an independent director of Vifor Pharma. Presently, he is an independent director of Calypso Biotech (Geneva, Switzerland), OSE Immunotherapeutics (Paris, France) and ImmunoRx Pharma (Wilmington, Delaware).

Dr Klaas Zuideveld, Versameb chief executive officer, said: "Dr. LeBeaut's has been a valuable member of our board since July 2023 and has extensive experience that has been instrumental in securing the recent Investigational New Drug clearance by the FDA of our lead candidate, VMB-100, for the treatment of Stress Urinary Incontinence (SUI). We look forward to his continued guidance as chairman of Versameb's board of directors, particularly ahead of initiating our first-in-human clinical study of VMB-100 as a therapeutic option for patients suffering SUI in the first half of 2024."